Abel Hall LLC’s Coherus Oncology CHRS Stock Holding History

Abel Hall LLC’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-12,249	Closed	-$9.88K	–	297
2025 Q1	$9.88K	Sell	12,249 -2,056	-14%	-$2.37K	0.01%	190
2024 Q4	$19.7K	Buy	+14,305	New	+$16K	0.01%	157

Other funds holding CHRS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CWG

C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Abel Hall LLC's CHRS Position: Q2 2025 in Review

Abel Hall LLC sold out of Coherus Oncology (CHRS) in Q2 2025, closing a stake of 12,249 shares — an estimated $9.88K sold.

Abel Hall LLC first reported a position in CHRS in Q4 2024 and held it in 2 quarters. The position peaked at $19.7K in Q4 2024. 112 funds tracked by Wall St. Rank hold CHRS as of Q2 2025.

Abel Hall LLC reported no remaining Coherus Oncology position as of Q2 2025 after selling out during the quarter.
Abel Hall LLC sold 12,249 Coherus Oncology shares in Q2 2025, an estimated $9.88K.
Abel Hall LLC first reported a position in Coherus Oncology in Q4 2024 and held it in 2 quarters.
Abel Hall LLC's Coherus Oncology position peaked at $19.7K in Q4 2024.
112 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2025.

Based on Abel Hall LLC's 13F filing for Q2 2025, filed 23 Jul 2025.